Maud Brandely, formerly director of clinical development at Pierre Fabre Oncologie, has been appointed chief medical officer of Transgene SA, which is part of Institut Mérieux. At Pierre Fabre, Dr Brandely oversaw clinical trials for the company’s cancer programs and supported the registration of vinorelbine for breast and non-small cell lung cancers.
Separately, John Felitti, previously of Sanofi SA, has joined Transgene as general counsel and corporate secretary. At Sanofi, he was associate vice president for corporate law, finance and securities law.
Transgene announced the appointments on 17 March 2016.
Copyright 2016 Evernow Publishing Ltd